Examining medicine shortages and their consequences through economic, clinical, and economic lens
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
Enhancing Health Technology Assessment Transparency through Digital Innovation
Portugal’s national medicines agency is using digital innovation to bring greater openness to health technology assessment. INFARMED, I.P. has released a new public platform called “Tracker de Processos” that allows anyone to follow, in real time, the progress of funding and reimbursement applica...
Establishing a Vaccine Confidence Strategy: EMA’s New Advisory Group Tackles Public Health ...
The European Medicines Agency (EMA) has introduced a dedicated vaccine confidence strategy through the launch of a new advisory group. Comprising more than 20 high-level experts from academia, healthcare, patient organisations, and public health bodies, the group held its first meeting on 29 Apri...
Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector
In an interview with Adrian van den Hoven, Director General of Medicines for Europe, meaningful progress made in 2025 is highlighted, including the political agreement on the new EU ph...